One compound, FG-2216, has been shown to increase EPO levels [135] in patients with end-stage renal disease, while another compound from the company, FG-4592, has been shown to correct anemia in patients with peritoneal dialysis [136] and patients undergoing dialysis without iron supplementation [137]. This evidence concerns the gene EPO and anemia.